<DOC>
	<DOCNO>NCT02667574</DOCNO>
	<brief_summary>Open-label , non-comparative , multicenter , phase II study Vismodegib patient locally advanced BCC .</brief_summary>
	<brief_title>Study Evaluating Interest Vismodegib Neo-adjuvant Treatment Basal Cell Carcinoma ( BCC )</brief_title>
	<detailed_description>Enrolled patient receive continuous once-daily oral dose Vismodegib dosage 150 mg ( accordance product SmPC ) per administration . One cycle therapy define 28 day treatment . The treatment renew month depend product tolerance . The trial consist Screening Period ( Day -28 -1 ) , Treatment Period ( Day 1 BOR ) , one End Treatment Visit , one Surgery Visit 8 Safety Follow-Up Visits last dose Vismodegib ( +/- 5 day ) . Day 1 study define first day patient receive Vismodegib .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>1 . Patients BCC , surgery stage A , B C ( cf . Appendix 3 : Definition surgery stage ) , diameter ≥ 3cm zone intermediate risk tumor recurrence BCC diameter ≥ 2 cm zone higher risk tumor recurrence . According HAS recommendation , two zone take consideration : Zones intermediate risk tumor recurrence : forehead , cheek , chin , neck scalp Zones high risk tumor recurrence : nose periorificial site cephalic extremity 2 . The decision include patient study take Pluridisciplinary Committee Meeting ( RCP ) . During RCP , radiotherapy consider inadequate treatment . ( If radiotherapist absent meeting , opinion document patient 's medical record ) . 3 . Written inform consent 4 . Age ≥ 18 year old 5 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 , 1 , 2 6 . At least one histologically confirm lesion ... 7 . Patients Gorlin syndrome may enroll study must meet inclusion criterion 8 . Patients measurable and/or nonmeasurable disease ( defined RECIST , v1.1 ) 9 . Adequate organ function , evidence follow laboratory result : Hemoglobin &gt; 8.5 g/dL Granulocyte count ≥ 1000/μL Platelet count ≥ 75,000/μL Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 × ULN within 3 × ULN patient document Gilbert syndrome 10 . Negative serum pregnancy test within 7 day prior commencement dose premenopausal woman . Women nonchildbearing potential may include either surgically sterile postmenopausal ≥ 1 year . 11 . Women childbearing potential must use one highlyeffective method contraception one barrier method contraception treatment 24 month final dose . Highlyeffective method contraception define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly ( e.g. , implant , injectables , intrauterine device ; refer Appendix 8 detail ) . At discretion Investigator , acceptable method contraception may include total abstinence . ( Periodic abstinence [ e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception. ) . 12 . For male patient female partner childbearing potential , agreement top use condom spermicide , even vasectomy , sexual intercourse partner treat Vismodegib two month completion study treatment 13 . For male patient , agreement donate semen study 24 month discontinuation Vismodegib 14 . Agreement donate blood blood product study least 24 month discontinuation Vismodegib . 15 . Life expectancy &gt; 12 week 16 . Patients cover Health Insurance System 1 . Inability unwillingness swallow capsule 2 . Patients BCC situate head neck area 3 . Pregnancy lactation 4 . Concurrent nonprotocolspecified antitumor therapy ( e.g. , chemotherapy , target therapy photodynamic therapy 5 . Chemotherapy within 4 week prior enrollment 6 . Participation another clinical trial within 4 week prior enrollment 7 . Radiotherapy within 6 month prior enrolment 8 . Metastatic BCC 9 . Uncontrolled medical illness infection require treatment intravenous antibiotic . 10 . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication . 11 . Patients rare hereditary problem galactose intolerance , primary hypolactasia glucosegalactose malabsorption ( accord product SmPC ) . 12 . Patients unable unwilling comply protocol requirement 13 . Patients emergency situation 14 . Patients keep detention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>basal cell carcinoma</keyword>
	<keyword>surgery</keyword>
	<keyword>stage</keyword>
	<keyword>vismodegib</keyword>
</DOC>